Objectives: The objective of this clinical trial was to assess the safety and efficacy of carotid
BAT in advanced HF. Background: Increased sympathetic and decreased parasympathetic …

Background This study demonstrated the safety and effectiveness of baroreflex activation
therapy (BAT) in patients with heart failure with reduced ejection fraction (HFrEF). Objectives …

Aims Increased sympathetic and decreased parasympathetic activity contribute to heart
failure (HF) symptoms and disease progression. Carotid baroreceptor stimulation (baroreflex …

Heart failure with preserved ejection fraction (HFpEF) is a substantial public health issue,
equal in magnitude to heart failure with reduced ejection fraction. Clinical outcomes of …

Aims Heart failure (HF) pathophysiology is believed to be mediated by autonomic
dysfunction, including chronic sympathoexcitation and diminished baroreflex sensitivity …

Aims Heart failure with reduced ejection fraction (HFrEF) remains associated with high
morbidity and mortality, poor quality of life (QoL) and significant exercise limitation …

WO2006041664A2 - Baroreflex activation and cardiac resynchronization for heart failure treatment
- Google Patents WO2006041664A2 - Baroreflex activation and cardiac resynchronization for …

Objectives: We sought to determine the effect of baroreflex activation therapy (BAT) on
systolic blood pressure (SBP) in patients with resistant hypertension. Background: The …

Background Outcomes of heart failure (HF) have improved dramatically with the use of
blockers of the sympathetic and renin-angiotensin-aldosterone systems, as well as with …

Background: The ANTHEM-HFrEF (Autonomic Regulation Therapy to Enhance Myocardial
Function and Reduce Progression of Heart Failure with Reduced Ejection Fraction) pivotal …